Document Detail


Endothelial dysfunction and nitric oxide enhancing therapy: a new approach to the treatment of heart failure.
MedLine Citation:
PMID:  15470301     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Despite ethnic differences in heart failure prevalence, risk profiles, and outcomes, no clinical trials have been designed to prospectively examine the mechanisms responsible for these differences. The African-American Heart Failure Trial is the first prospective trial designed to test a novel therapy that enhances endothelial function and nitric oxide bioavailability in African-American patients with advanced heart failure.
Authors:
Anne L Taylor
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Congestive heart failure (Greenwich, Conn.)     Volume:  10     ISSN:  1527-5299     ISO Abbreviation:  Congest Heart Fail     Publication Date:    2004 Sep-Oct
Date Detail:
Created Date:  2004-10-07     Completed Date:  2005-02-03     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9714174     Medline TA:  Congest Heart Fail     Country:  United States    
Other Details:
Languages:  eng     Pagination:  237-42     Citation Subset:  IM    
Affiliation:
University of Minnesota Medical School,420 Delaware Street S.E., MMC 293, Minneapolis, MN 55455, USA. taylo135@umn.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
African Americans
Aged
Aged, 80 and over
Drug Therapy, Combination
Endothelium, Vascular / drug effects*,  physiopathology
Female
Heart Failure / drug therapy*,  ethnology,  physiopathology
Humans
Hydralazine / pharmacology,  therapeutic use*
Isosorbide / pharmacology,  therapeutic use*
Male
Middle Aged
Nitric Oxide / physiology*
Prospective Studies
Treatment Outcome
Chemical
Reg. No./Substance:
10102-43-9/Nitric Oxide; 652-67-5/Isosorbide; 86-54-4/Hydralazine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Decompensated heart failure: is there a role for the outpatient use of nesiritide?
Next Document:  Mechanisms and treatment of anemia in chronic heart failure.